<DOC>
	<DOCNO>NCT01477866</DOCNO>
	<brief_summary>The main aim present study test efficacy safety CITOGENEX administration patient colon-rectal cancer .</brief_summary>
	<brief_title>Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer</brief_title>
	<detailed_description>CITOGENEX dietary supplement insoluble polysaccharide , Lactobacillus Casei ( specific type ) Bifidobacterium Lactis ( specific type ) . These subspecies probiotic bacteria show effective improving immunity . Several trial currently underway , order evaluate effect probiotics potential novel therapy addition traditional therapeutic approach . Although probiotic play anti-tumor action per se , agent may significantly contribute decrease typical side effect due traditional anti-tumor treatment , gastrointestinal symptom , immunity deficit , well alteration gut lymphoid tissue . It therefore expect CITOGENEX may several significant beneficial effect patient anti-tumor treatment . In order test hypothesis , perform randomize , single-blind , two-arms , prospective study patient colon-rectal cancer .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>stage IIIaIIIc ( AJCC/TNM )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>